This Egyptian project is going to change the world of plasma
Grifols Egypt will inaugurate its first phase in October 2026, targeting 3 million liters of plasma collection by 2029 and reducing Egypt's €100M annual import dependency. The project has already created 1,500 direct jobs and 14,000 indirect jobs; 186,000 new jobs are projected through 2029 with over €700M total economic impact.
- 180 million euros additional investment through 2029
- First phase opens October 2026; full operation by 2030
- Projected 3 million liters of plasma collection by 2029, up from 1 million in 2026
- 186,000 new jobs expected 2026-2029; 1,500 direct jobs created to date
- Egypt currently spends ~100 million dollars annually on plasma imports
Grifols is investing an additional €180 million in Egypt through 2029 to build Africa's largest plasma processing facility, while receiving interest from a European country for a similar project.
Grifols is doubling down on Egypt. The Spanish pharmaceutical company has approved an additional 180 million euros in investment through 2029 for its Egyptian joint venture, money that will flow into what is already shaping up as the largest plasma processing facility in Africa and the Middle East. By October of this year, the first phase of the sprawling complex—situated in Egypt's new administrative capital—will open its doors. When fully operational in 2030, the 100,000-square-meter facility will house everything needed to turn donated plasma into finished pharmaceutical products: collection centers, processing plants, a fully automated testing laboratory, and integrated logistics.
The scale of the commitment reflects how central Egypt has become to Grifols' global strategy. The company has already sunk 280 million euros into the project since its inception in 2020, when the Egyptian government approached them with a straightforward problem: the country was spending roughly 100 million dollars annually to import plasma-derived medicines from abroad. Grifols saw an opportunity to build something that had never existed in the region—a complete, vertically integrated plasma ecosystem. The partnership, formalized as Grifols Egypt for Plasma Derivatives, was born from that conversation.
The expansion timeline is ambitious but methodical. Logistics and sorting facilities will be complete by the third quarter of 2026. The fractionation units—where plasma is separated into its therapeutic components—will be ready by the end of 2027. The final purification and product finishing stages will conclude in 2029. Currently, Grifols Egypt operates 16 donation centers across the country; four more will open this year, with plans to reach 40 eventually. The company projects plasma collection will hit one million liters in 2026 and triple to three million liters by 2029. That shift from dependency to self-sufficiency carries real weight: Egypt will no longer need to import what it can now produce.
The human infrastructure behind these numbers is substantial. More than 1,500 direct jobs have been created so far, alongside 14,000 indirect positions in supporting industries. Between 2026 and 2029, the project is expected to generate 186,000 new jobs in total. The economic footprint extends beyond employment: the total impact of the investment is projected to exceed 700 million euros when you account for direct, indirect, and induced effects. Since the project began, Grifols has delivered more than 1.6 million vials of plasma-derived medicines to Egyptian hospitals and public health centers, and conducted over 120,000 free medical screenings for donors. The accumulated clinical benefit of these therapies is valued at more than 80 million euros in health gains.
What makes this model exportable is that it solves a problem many countries face. The European Union has already taken notice. According to Tomás Dagá, vice president of GEPD's board, an unnamed European country has expressed serious interest in replicating the Egyptian model. That government, like Egypt's, wants autonomy in plasma supply and freedom from dependence on American sources. The two parties are scheduled to meet in the coming weeks. Dagá was emphatic about the significance: "This Egyptian project is going to change the world of plasma. It's being well received by Europe."
The timing matters. The COVID-19 pandemic exposed how fragile global plasma supply chains are; when exports from the United States froze, countries without domestic capacity suffered. Grifols is now positioned to help reshape that landscape. The European Medicines Agency approved Grifols Egypt's entire value chain in December 2025, clearing the way for the company to optimize its global plasma network and progressively reduce reliance on American supply for markets outside the United States. Between 2025 and 2029, Grifols expects non-US plasma supply to more than double, driven largely by Egypt.
The model depends on one thing that Egypt has managed to provide: political stability and the willingness to change its laws. The country updated its legislation to allow donor compensation—a critical detail, since most of the world's plasma historically comes from the United States, where paid donation is legal. Many European countries prohibit compensating donors, yet they import plasma from countries where donors are paid. Grifols Egypt currently has roughly 80,000 active donors and is working to expand that pool. In the United States, by contrast, the company has access to nearly one million donors. The compensation structure is deliberate: donors are paid for their time and effort, not per donation. The company encourages frequent, recurring donors—ideally once weekly rather than the legal maximum of twice weekly—because consistency and relationship matter more than volume when it comes to plasma quality.
Citas Notables
This Egyptian project is going to change the world of plasma; it's being well received by Europe.— Tomás Dagá, vice president of Grifols Egypt for Plasma Derivatives
The government wanted stability in this segment and to be self-sufficient in plasma access for treatments.— Tomás Dagá, describing interest from an unnamed European country
La Conversación del Hearth Otra perspectiva de la historia
Why Egypt specifically? There are other countries with lower costs and growing pharmaceutical sectors.
Egypt solved a problem that mattered to Grifols: the government came to them wanting to build something that didn't exist in the region. That's different from Grifols imposing a model. The government wanted autonomy, not dependency. That alignment is rare.
The donor compensation piece—that's legally contentious in Europe. How does Grifols navigate that?
They don't try to change European law. They work within it. But they're also pointing out the contradiction: Europe bans paid donation but buys plasma from countries where donors are paid. Egypt changed its own laws to allow compensation because it wanted to build this capacity. That's a sovereign choice.
186,000 new jobs by 2029 seems like a very large number. Is that realistic?
It includes direct, indirect, and induced employment—everyone from the people working in the facility to the truck drivers supplying it to the restaurants feeding those workers. The direct number is 1,500 so far. The multiplier effects are real, but yes, the total figure is a projection, not a guarantee.
What does a European country gain by replicating this model?
The same thing Egypt gained: they stop sending money abroad for something they can produce domestically. They build a strategic asset. And they reduce their vulnerability to supply shocks, which COVID proved is a real risk.
Is this about Grifols making money, or about solving a public health problem?
Both. Grifols is a for-profit company. But the structure—a joint venture with the government, local job creation, free medical screenings for donors—suggests they're not extracting value and leaving. They're building something that stays.
What happens if the European deal materializes?
You'd see the model replicate. A second facility, different regulatory environment, different donor pool. It would prove the model works beyond Egypt, which is what Grifols is betting on.